Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value.
Board of Directors
David Meeker, M.D. – Chairman
James Cassella, Ph.D.
James Cassella, Ph.D. has served as a member of our board of directors since February 2020. Dr. Cassella has served as Chief Development Officer for Concert Pharmaceuticals, Inc., a publicly-traded biotechnology company, since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions, including Senior Vice President of Clinical Research and Development at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in Psychology from the University of New Haven.
Co-Founder, President and CEO
Jennifer Good is our co-founder and has served as a member of our Board of Directors and as our President and Chief Executive Officer since our inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals Co., or Penwest, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of Rhythm Pharmaceuticals, a publicly traded biopharmaceutical company, since June 2019. Previously, Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by Catalent, Inc. in August 2018. Ms. Good has also served as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, since 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Our Board of Directors believes that Ms. Good’s in-depth knowledge of our business from serving as our founder, President and Chief Executive Officer and her perspective and experience as an executive and a director at publicly traded and privately held companies in the life sciences industry, provide her with the qualifications and skills to serve on our Board of Directors.
Chief Financial Officer
Lisa Delfini has served as our Chief Financial Officer since August 2021. Ms. Delfini served as a Financial Accounting and Advisory Services Partner at Marcum LLP, an accounting and advisory services company, from 2015 until August 2021, specializing in providing services to companies in the life science and high-tech industries. Previously, she worked at General Electric Company, a multinational conglomerate, as Global Controller for the GE Corporate Technical Center of Excellence from 2011 to 2014 and as Global Controller for the GE Industrial Solutions division from 2014 to 2015. Ms. Delfini began her career at Deloitte & Touche LLP, where she worked for 16 years, completing her time there as a Client Service Partner. Ms. Delfini received a B.S. in accounting from Lehigh University and is a Certified Public Accountant licensed by the state of Connecticut.
David Clark, MBChB, MRCP
Chief Medical Officer
David Clark, MBChB, MRCP has served as our Chief Medical Officer since November 2022. Prior to joining us, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, Inc., a biopharmaceutical company, from November 2020 to September 2022, leading the company’s clinical development, regulatory and medical affairs teams. Prior to that, he served as Chief Medical Officer for Aldeyra Therapeutics, Inc., a biotechnology company, from January 2016 to May 2020. He has also served as Chief Medical Officer for Wilson Therapeutics and NormOxys, Inc. and held senior leadership positions at TransTech Pharma, Pfizer Inc., and GlaxoSmithKline, formerly known as Smithkline Beecham. Dr. Clark holds a Bachelor of Medicine and Surgery (MBChB) from the University of Edinburgh Medical School and is admitted to Membership of the Royal College of Physicians (MRCP). Dr. Clark also completed a research fellowship in respiratory medicine in the United Kingdom.
Thomas Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Thomas Sciascia, M.D., is our co-founder and has served as our Chief Scientific Officer since November 2022. Prior to that, he served as our Chief Medical Officer from our inception, in March 2011, until November 2022. Previously, Dr. Sciascia was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest from 2001 to 2010. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. from 1997 to 2000 as a consultant to pharmaceutical and biotechnology companies. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc) from 2000 to 2001. Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts.
Farrell Simon, Pharm.D.
Chief Commerical Officer
Farrell Simon, Pharm.D. has served as our Chief Commercial Officer since February 2023. Prior to that, he served as our Senior Vice President, Head of Commercial and Strategy, from February 2022 until February 2023 and Vice President, Head of US Marketing, from September 2020 until February 2022. Previously, Dr. Simon was the Senior Director, Chief of Staff to the Biopharma Group President at Pfizer Inc. and a member of the biopharma executive leadership team from January 2018 to September 2020. Prior to joining Pfizer, Dr. Simon gained general management, marketing, and medical affairs experience at Procter & Gamble. Dr. Simon is the founder and Chief Executive Officer of The Simon Cancer Foundation and is on the board of directors for the Greater New Haven Chamber of Commerce. He previously held positions on the advisory boards for the business school and the College of Pharmacy at the University of Florida. Dr. Simon holds both an M.B.A. and a Pharm.D. from the University of Florida.
VP, Medical Affairs
Danine Summers is our Vice President of Medical Affairs at Trevi. Danine has over 35 years of experience in the pharmaceutical industry, the last 20 years in dermatology and more recently in pulmonology. She started her career in field sales with Merck Sharp & Dohme and then moved on to American Scientific Products and Roche Labs. While at Roche Danine completed her MBA and transitioned from sales to marketing. She has 18 years of experience in various areas of Marketing including time with FCB Healthcare (clients included Syntex, Gilead, Allergan and Neutrogena) and Connetics Pharmaceuticals, where she built out the marketing department for the company. For the past 15 years Danine has focused on building the Medical Affairs function in companies where it did not previously exist. This included work done at Medicis, Anacor Pharmeceuticals and Menlo Therapeutics. Further, she has led and/or participated in over 10 product launches in her career. Danine joined Trevi Therapeutics in early 2020.
Katherine Takaki, Ph.D.
VP, Global Regulatory Affairs
Katherine Takaki, Ph.D. is the VP of Global Regulatory Affairs at Trevi. She has over 30 years of pharmaceutical industry experience in regulatory strategy, global project and team management, and drug discovery. Before joining Trevi, Katherine served as Vice President, Global Regulatory Affairs at Iterum Therapeutics where she helped build out the regulatory group to support the Company’s regulatory strategy and operations. Prior to that, she held leadership positions at Bristol Myers Squibb supporting multiple therapeutic areas and covering all stages of drug discovery and development. She was the global project manager for the team that developed Baraclude for the treatment of hepatitis B and launched it in markets worldwide. She was subsequently the Group Director, Head of Regulatory Strategy Marketed Products at Bristol Myers Squibb. Katherine holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and a B.S. in Chemistry from the University of Hawaii at Manoa.
VP, Clinical Operations
Paula Buckley is the VP of Clinical Operations at Trevi. She has almost 35 years pharmaceutical industry experience in Analytical Chemistry, Quality Assurance and Clinical Operations. Before joining Trevi Paula served as VP Quality Assurance/Control at Penwest, as well as several leadership roles in Quality Assurance and Control in companies such as Bayer, Anesiva and I-Health. During her years at Bayer, she worked in leadership roles in Analytical Chemistry in several therapeutic areas. Paula received her Bachelor of Science degree at Southern CT State University in 1987.